Level Four Advisory Services’s Cidara Therapeutics CDTX Stock Holding History

Level Four Advisory Services’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,396	Closed	-$21.1K	–	769
2022 Q4	$21.1K	Buy	+1,396	New	+$16.7K	﹤0.01%	661

Other funds holding CDTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Level Four Advisory Services's CDTX Position: Q1 2023 in Review

Level Four Advisory Services sold out of Cidara Therapeutics (CDTX) in Q1 2023, closing a stake of 1,396 shares — an estimated $21.1K sold.

Level Four Advisory Services first reported a position in CDTX in Q4 2022 and held it in 1 quarter. The position peaked at $21.1K in Q4 2022. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2023.

Level Four Advisory Services reported no remaining Cidara Therapeutics position as of Q1 2023 after selling out during the quarter.
Level Four Advisory Services sold 1,396 Cidara Therapeutics shares in Q1 2023, an estimated $21.1K.
Level Four Advisory Services first reported a position in Cidara Therapeutics in Q4 2022 and held it in 1 quarter.
Level Four Advisory Services's Cidara Therapeutics position peaked at $21.1K in Q4 2022.
54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2023.

Based on Level Four Advisory Services's 13F filing for Q1 2023, filed 5 Jun 2023.